Filtered Listing Testing
A promising new treatment for individuals suffering from stroke, concussion, and traumatic brain injury, known risk factors for dementia, has received approval from the U.S. Food & Drug Administration to move into Phase 2 clinical trials. Learn more.
Learn how our funded scientists are advancing new ways of diagnosing Alzheimer’s disease earlier and more accurately.
Alzheimer’s Disease Research, a BrightFocus Foundation program, joined over 4,500 scientists, physicians, and industry leaders from 70 countries at the annual International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Lisbon, Portugal. Read our key takeaways.
The company behind the first-of-its-kind blood-based screening test for Alzheimer’s disease—rooted in pivotal early BrightFocus support—has received a $15 million investment that will broaden access to the blood test for patients and doctors.
A National Institute on Aging senior investigator breaks down amyloid trials: what went wrong and what must come next.
Immune cells undergo non-inherited genetic changes that are associated with higher Alzheimer’s risk.
Age-related macular degeneration is a leading cause of vision loss in Americas aged 60 and older. Guest speaker Gayatri S. Reilly, MD will answer questions and share all the facts you need to know about both wet and dry macular degeneration.
Brightfocus supports a groundbreaking $28M investment by the Canadian Institutes of Health Research to bolster early-career health researchers from historically under-recognized groups.
BrightFocus President and CEO Stacy Pagos Haller spoke with WebMD about the latest breakthroughs in macular degeneration research.
Learn more about the biological hallmarks of Alzheimer’s disease.